Lanadelumab safety and immunogenicity: results from the phase 3 help study

Lanadelumab, a fully human monoclonal antibody targeting plasma kallikrein, effectively prevented attacks in patients with hereditary angioedema (HAE) in the phase 3 HELP Study (NCT02586805).

Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: D. Johnston, A. Banerji, M. Riedl, B. Zuraw, W. Lumry, J. Bernstein, H. Li, P. Lu, J. Hao, R. Gower Tags: P166 Source Type: research